Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT 201 for simultaneous treatment of upper facial lines
2019-004113-13Phase 3Completed
- Sponsor
- Merz
- Start
- Apr 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of botulinum toxin type A in upper facial lines, glabellar furrowing, lateral canthal rhytides and 1 more (3 arms), sponsored by Merz. Primary endpoint: Primary efficacy endpoints. Started Apr 2020; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
upper facial linesglabellar furrowinglateral canthal rhytidesrhytides
Beyond the preview
Go deeper on 2019-004113-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004113-13.